Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
quadrivalent human papillomavirus recombinant vaccine or nonavalent human papillomavirus vaccine · 1 trial · 2 indications
The prevalence of HPV vaccine initiation in cancer survivors ages 9 to 26 years
To demonstrate the non-inferiority of the antibody responses to the HPV vaccine in cancer survivors ages 9 to 26 years when compared to antibody responses of age- and sex-matched historical healthy population.
To demonstrate comparable safety/tolerability of the HPV vaccine in cancer survivors ages 9 to 26 years when compared to age- and sex-matched general population.
| Arm | Type | Description |
|---|---|---|
| Prevention (vaccine therapy) | EXPERIMENTAL | Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks. |
| Name | Type | Description |
|---|---|---|
| quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) | BIOLOGICAL | Given IM |
| laboratory biomarker analysis | OTHER | Correlative studies |
| survey administration | OTHER | Ancillary studies |
| medical chart review | OTHER | Ancillary studies |
Inclusion Criteria: * AIM 1 (SURVEY) (AIM 1 is closed to enrollment) * Cancer survivor * Between 12 and 60 months after completion of cancer therapy (chemotherapy, radiation, hematopoietic cell transplant \[HCT\]) * Scheduled for a return clinic visit at one of the participating institutions * Engl...